Business Wire

The Lancet Respiratory Medicine:New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids

Del

Boehringer Ingelheim today announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment.1 In WISDOM, for 80 percent of patients, the use of ICS on top of Spiriva®‡ and a LABA** had no additional benefit in reducing the risk of exacerbations or ‘flare-ups,’ compared to Spiriva®‡ and a LABA** without ICS. The post-hoc analysis shows that these patients can be easily identified by measuring the level of eosinophils in their blood. Patients with levels lower than 4 percent (300 cells/µL) had no additional exacerbation benefit with the inclusion of ICS in their regimen.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160407006617/en/

The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from  ...

The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids (Photo: Business Wire)

Exacerbations significantly contribute to the impact of COPD, often lead to the patient being admitted to hospital,2 and can increase the risk of a patient dying.3 GOLD recommends the use of ICS-containing therapy only in COPD patients with severe to very severe lung function impairment and/or at high risk of exacerbations (GOLD C/D)4 – the patient population studied in WISDOM. Even within this severe population, only a small minority of patients in the study benefited from the inclusion of ICS to reduce their exacerbation risk.1 It is recognised that long term use of ICS treatments may be associated with a risk of serious side effects including pneumonia, osteoporosis and diabetes onset and progression.5,6,7

The WISDOM post-hoc analysis demonstrates that using the simple and commonly performed eosinophil blood count may provide a practical tool to help doctors identify the small subset of patients who may benefit from the addition of ICS to Spiriva+LABA therapy. This post-hoc analysis is published online in the journal The Lancet Respiratory Medicine.

“Long acting bronchodilators are a mainstay therapy in COPD management, however in clinical practice ICS is widely used across all COPD stages,” said study investigator Peter Calverley, Professor of Pulmonary and Rehabilitation Medicine, University of Liverpool, UK. “Previously, it has been difficult to determine the subset of patients who respond to ICS. These findings will help physicians more confidently identify which patients may benefit from ICS therapy, helping minimise exposure to the risk of side effects related to long-term ICS use.”

The 52-week, large-scale WISDOM study evaluated the effect of ICS withdrawal in patients with severe to very severe COPD with a history of exacerbation, while receiving Spiriva®‡ and a LABA.8 This new post-hoc analysis from WISDOM found that the 20 percent of patients who benefited from a reduced exacerbation risk due to the continued use of ICS on top of a combination of Spiriva®‡ with a LABA had higher levels of blood eosinophils (≥300 cells/µL; more than 4 percent).1

“These results are thought-provoking and add to the current debate about the appropriate use of ICS therapy in COPD,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “We look forward to further discussion and investigation of this important topic.“

Future prospective studies are needed to provide further evidence to confirm these findings. In the WISDOM study population, complete ICS withdrawal was associated with a small reduction in trough FEV1. No relationship was observed between blood eosinophil count and change in lung function with ICS withdrawal.

COPD is a serious but manageable lung disease, which is estimated to affect 210 million patients worldwide.9 Total deaths from COPD are projected to increase by more than 30 percent in the next 10 years; COPD is predicted to become the third leading cause of death by 2030.10

For the full results please refer to The Lancet Respiratory Medicine paper here: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)00100-4/abstract

For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2016/08_april_2016_copd.html

* Inhaled corticosteroids

Withdrawal of Inhaled Steroids During Optimised Bronchodilator Management

Once-daily tiotropium 18µg administered via HandiHaler® (tiotropium bromide inhalation powder)

§ Long-acting beta2-agonist

** Twice-daily salmeterol 50µg

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Carolin Grob
Phone: +49 6132 – 77 182603
Fax: +49 6132 – 77 6601
Email: carolin.grob@boehringer-ingelheim.com
www.boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab23.10.2017 11:15Pressemelding

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005462/en/ Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (“AD”). The expanded agreement leverages each company’s respective geographic strengths for commercialization and adjusts the respective share of profits from potential sales of aducanumab. Biogen will receive 55

Open Letter from Mats Granryd, Director General, GSMA23.10.2017 11:01Pressemelding

Dear Ministers, As you are no doubt aware, European citizens and businesses rely on mobile networks to socialise, do business and access information everyday in every corner of every Member State of the Union. The social and economic activity that rides over this digital infrastructure drives economic growth, shapes future innovation and fosters more inclusive societies. As you prepare to convene at tomorrow’s Ministerial Council Meeting, I must express my grave concerns on the current state of discussions on the proposed European Electronic Communication Code (the Code). Although the European Union’s vision of a ‘Gigabit Society’, and recent discussions amongst the European Heads of State, demonstrate a strong ambition to recapture the region’s digital leadership and harness the full power of digital to drive growth, jobs and competitiveness, we do not see action foc

San Francisco 49ers and IDEMIA Announce Strategic Partnership to Enhance Fan Experience23.10.2017 09:30Pressemelding

The San Francisco 49ers and IDEMIA announced a new multi-year partnership to promote and implement identity and security services from IDEMIA’S IdentoGO solution, the country’s preeminent identity-related service provider and exclusive provider of TSA Pre✓®, at Levi’s® Stadium. In addition to offering TSA Pre✓® enrollment opportunities at 49ers home games, IDEMIA will equip the stadium with biometric-based technology to assist in fan experience and security in the near future. “We’re always looking for innovative ways to enhance security at Levi’s ® Stadium and IDEMIA’S IdentoGO technology complements our efforts as we strive to provide expedited entry for pre-approved customers,” said Jim Mercurio, 49ers Vice President of stadium operations and Levi’s® Stadium general manager. “We look forward to working with IDEMIA to jointly deploy the first-ever Trusted Fan Progr

E Ink and LTS Partner to Develop Smart Patch to Improve Medical Management23.10.2017 07:00Pressemelding

E Ink Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and LTS Lohmann-Therapie Systeme AG, “LTS” leading in the development and manufacturing of transdermal therapeutic systems, today announced their partnership to develop a “Smart Patch” prototype. The Smart Patch prototype is a transdermal therapeutic system (TTS) that delivers medication to patients in a convenient, controlled and comfortable manner and features an E Ink display to deliver and convey relevant information about patch performance. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005449/en/ The “Smart Patch” prototype features an E Ink display to convey relevant information about patch performance to patients. (Photo: E Ink Holdings) According to a report conducted by the New England Healthcare Institute

MaxLinear and Corinex to Use G.hn for Open Smart Metering Solution23.10.2017 06:00Pressemelding

MaxLinear, Inc. (NYSE:MXL), a leading provider of radio frequency (RF), analog and mixed-signal integrated circuits for the connected home, wired and wireless infrastructure, and industrial and multimarket applications and Corinex, a unique supplier of broadband solutions (BPL) for smart metering and smart grid infrastructure improving grid operational efficiency, security and integration of renewable energy and EV’s today announced that they will cooperate to create a broadband utility infrastructure solution based on standard ITU-T G.hn technology to enable smart metering and other smart grid applications. The G.hn solution will address the growing interest of electricity utilities in leveraging broadband powerline networks for Smart Grid applications, while ensuring multi-vendor interoperability, openness and easy integration into a wide range of Smart Meters and Smart Grid infrastr

NTT Communications to Share Industry Views with Global Carrier Community at Capacity Europe 2017 in London23.10.2017 06:00Pressemelding

Executives from NTT Communications (NTT Com), the global data and IP services arm of Fortune Global 500 telecom leader NTT (TYO: 9432), will play a prominent speaking role at this year’s Capacity Europe conference in London – Europe’s largest annual meeting for the global carrier community. During the conference, which runs October 24-26 at the Intercontinental London 02, NTT Com executives will participate in three panels that provide expert analysis and perspective on trending industry topics including the Internet of Things (IoT), network security and the importance of innovation and leadership. NTT Com is in a unique position to address global wholesale trends and opportunities as the global carrier consistently ranks as one of the top IP network providers worldwide. “Coming together as an industry to share insights and perspective is not only beneficia

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom